Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Payables (2016 - 2025)

Capricor Therapeutics has reported Payables over the past 15 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Payables at $1.7 million for Q4 2025, down 49.61% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (down 49.61% YoY), and the annual figure for FY2025 was $1.7 million, down 49.61%.
  • Payables for Q4 2025 was $1.7 million at Capricor Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Payables for CAPR hit a ceiling of $6.8 million in Q3 2023 and a floor of $1.7 million in Q4 2025.
  • Median Payables over the past 5 years was $4.3 million (2022), compared with a mean of $4.4 million.
  • Biggest five-year swings in Payables: skyrocketed 189.44% in 2021 and later plummeted 58.36% in 2025.
  • Capricor Therapeutics' Payables stood at $3.1 million in 2021, then soared by 55.14% to $4.8 million in 2022, then increased by 29.28% to $6.3 million in 2023, then tumbled by 47.46% to $3.3 million in 2024, then tumbled by 49.61% to $1.7 million in 2025.
  • The last three reported values for Payables were $1.7 million (Q4 2025), $2.7 million (Q3 2025), and $4.8 million (Q2 2025) per Business Quant data.